On August 31, 2023 MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, reported that the Company’s management will participate in the following upcoming investor conferences (Press release, MacroGenics, AUG 31, 2023, View Source [SID1234634802]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 18th Annual BioPharma Conference (Boston). Scott Koenig, M.D., Ph.D., MacroGenics’ President and CEO, will participate in an ADC/Next Gen Panel Discussion on Wednesday, September 6, 2023, at 10:30 am ET. MacroGenics’ management will also participate in one-on-one meetings.

H.C. Wainwright’s 25th Annual Global Investment Conference (New York). Scott Koenig, M.D., Ph.D., will provide a corporate presentation on Monday, September 11, 2023, at 2:30 pm ET. MacroGenics’ management will also participate in one-on-one meetings.

Webcasts of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics’ website at View Source The Company will maintain archived replays of these webcasts on its website for 30 days.